Partners & Sponsors

IPM has partnered with a variety of institutions to advance the dapivirine ring from concept to late-stage clinical trials in just seven years, each bringing complementary resources and scientific ingenuity to the ring licensure program:

Microbicide Trials Network (MTN):  Funded by the US National Institutes of Health, MTN is a worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. Given the dapivirine ring’s promise as a microbicide, MTN has partnered with IPM to advance the dapivirine ring licensure program and conduct the ASPIRE study. MTN will provide a list of its research centre sites when the study launches later this year.

Research center partners: IPM partners with local research centers in Africa to conduct clinical studies.  The following research centers are enrolling now for The Ring Study with an additional site expected to initiate in Rwanda soon:

Janssen R&D Ireland:  IPM is developing dapivirine for use as a microbicide through a royalty-free licensing agreement with Janssen R&D Ireland (previously Tibotec Pharmaceutials), one of the Janssen pharmaceutical companies of Johnson & Johnson.

QPharma: A Sweden-based contract developer and pharmaceuticals manufacturer with 35 years experience, QPharma is manufacturing the dapivirine vaginal rings for the licensure program using highly specialized equipment.

Donors:  IPM’s work to date has been supported by governments, foundations, and multilateral organizations including: Belgium, Canada, Denmark, France, Germany, Ireland, Netherlands, Norway, Spain, Sweden, the United Kingdom and the United States; the European Commission, the World Bank, UNFPA, the Bill & Melinda Gates Foundation, the Rockefeller Foundation, the OPEC Fund for International Development, and the MAC AIDS Fund. View IPM’s donor list.

See all IPM partners.